In this issue:
Real-world outcomes in myeloma patients with t(11;14)
Lower rates and delayed MRD in patients with t(11;14) MM
Genomic mechanisms of resistance to venetoclax in t(11;14) MM
Inferior survival in newly diagnosed patients in New Zealand
Rd is an effective and safe front-line therapy for elderly transplant-ineligible patients
Daratumumab at biochemical relapse delays clinical progression
Front-line SVRd promising for newly diagnosed disease with EMD
Hepta-refractory MM: profound genomic complexity, antigen loss and poor outcomes
MajesTEC-3: Teclistamab–daratumumab outperforms triplets for early RRMM relapse
Please login below to download this issue (PDF)